<div id="readability-page-1"><p>Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) fell 4.1% on Monday following insider selling activity. The stock traded as low as $15.37 and last traded at $15.48. 384,260 shares traded hands during trading, a decline of 75% from the average session volume of 1,549,865 shares. The stock had previously closed at $16.14.</p><div><p><span></span><span>Get <strong>Ginkgo Bioworks</strong> alerts:</span></p></div><p>Specifically,  insider Steven P. Coen sold 5,609 shares of the company's stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $15.00, for a total value of $84,135.00. Following the transaction, the insider directly owned 5,503 shares of the company's stock, valued at $82,545. This represents a 50.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research firms recently issued reports on DNA. Cowen  reissued a &#34;buy&#34; rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Ginkgo Bioworks in a research report on Saturday, September 27th. Wall Street Zen raised Ginkgo Bioworks from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 30th. Finally, BTIG Research increased their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a &#34;sell&#34; rating in a research report on Monday, August 25th. One equities research analyst  has rated the stock with a Buy rating and two have assigned  a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks presently has an average rating of &#34;Reduce&#34; and a consensus price target of $9.00.</p><p><b>View Our Latest Stock Analysis on DNA</b></p><h2>Ginkgo Bioworks Stock Performance</h2><p>The firm's 50 day moving average price is $12.35 and its 200-day moving average price is $9.80. The firm has a market capitalization of $914.05 million, a PE ratio of -2.63 and a beta of 1.54. </p><p>Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. The firm had revenue of $49.60 million for the quarter, compared to analyst estimates of $41.60 million.  Ginkgo Bioworks has set its FY 2025 guidance at  EPS. On average, equities research analysts expect that  Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year. </p><h2>Institutional Trading of Ginkgo Bioworks</h2><p>Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new stake in  Ginkgo Bioworks in the 2nd quarter valued at approximately $29,000.  Ameritas Investment Partners Inc. acquired a new position in shares of  Ginkgo Bioworks in the second quarter worth $45,000.  US Bancorp DE grew its stake in shares of  Ginkgo Bioworks by 43.5% in the first quarter. US Bancorp DE now owns 6,302 shares of the company's stock worth $36,000 after acquiring an additional 1,911 shares in the last quarter.  Daiwa Securities Group Inc. acquired a new position in shares of  Ginkgo Bioworks in the second quarter worth $71,000.  Finally, Police &amp; Firemen s Retirement System of New Jersey acquired a new position in shares of  Ginkgo Bioworks in the second quarter worth $99,000. Institutional investors and hedge funds own  78.63% of the company's stock. </p><h2>About Ginkgo Bioworks</h2> (Get Free Report)<p>Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Ginkgo Bioworks</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>3 Travel Stocks to Watch Heading Into the Holidays</li><li>Find and Profitably Trade Stocks at 52-Week Lows</li><li>Best Stocks Under $15? 3 Low-Priced Picks With Upside</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Behind D-Wave's Massive Week (And Why Rivals Also Popped)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ginkgo Bioworks Right Now?</h2><p>Before you consider Ginkgo Bioworks, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.</p><p>While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Ginkgo Bioworks (NYSE:DNA) shares fell 4.1% to $15.48 following insider selling by Steven P. Coen, who sold 5,609 shares at $15.00 each. The stock's trading volume dropped significantly, and analysts have mixed ratings, with one buy and two sell ratings. The company reported a quarterly loss of $1.10 per share but exceeded revenue expectations. Institutional investors hold 78.63% of the stock. Ginkgo Bioworks focuses on cell programming for various industries, including pharmaceuticals and agriculture.</p>

Ginkgo Bioworks (NYSE:DNA) Shares Down 4.1% Following Insider Selling